{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:04:27Z","timestamp":1793765067479,"version":"4.6.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-17-1-0653"],"award-info":[{"award-number":["W81XWH-17-1-0653"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-1-0010"],"award-info":[{"award-number":["W81XWH-22-1-0010"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-1-0061"],"award-info":[{"award-number":["W81XWH-22-1-0061"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH","award":["R01DK097112"],"award-info":[{"award-number":["R01DK097112"]}]},{"name":"NIH","award":["R21EB036323"],"award-info":[{"award-number":["R21EB036323"]}]},{"name":"NIH","award":["R37CA241486"],"award-info":[{"award-number":["R37CA241486"]}]},{"name":"NIH","award":["P50-CA211024"],"award-info":[{"award-number":["P50-CA211024"]}]},{"name":"Lee Family Foundation","award":["Lee Family Foundation"],"award-info":[{"award-number":["Lee Family Foundation"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00259-025-07287-y","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:18:22Z","timestamp":1745194702000},"page":"4092-4101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A pilot study of [18F]F-fluciclovine positron emission tomography\/computed tomography for staging muscle invasive bladder cancer preceding radical cystectomy"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3676-1800","authenticated-orcid":false,"given":"Thomas S. C.","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mofei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arda","family":"K\u00f6nik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Chun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin K.","family":"Bakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wolanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Preston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Mossanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himisha","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Jacene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"7287_CR1","first-page":"7","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"7287_CR2","doi-asserted-by":"crossref","unstructured":"Alfred Witjes J, Lebret T, Comp\u00e9rat EM et al. Updated 2016 EAU guidelines on Muscle-invasive and metastatic bladder Cancer. Eur Urol.71:462\u201375.","DOI":"10.1016\/j.eururo.2016.06.020"},{"key":"7287_CR3","doi-asserted-by":"crossref","unstructured":"Sathianathen NJ, Risk MC, Konety BR. Lymphadenectomy for Muscle-Invasive bladder Cancer and upper tract urothelial cell carcinoma. Urol Clin North Am. 2018.","DOI":"10.1016\/j.ucl.2017.12.006"},{"key":"7287_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","volume":"22","author":"TW Flaig","year":"2024","unstructured":"Flaig TW, Spiess PE, Abern M, et al. Bladder cancer, version 3.2024: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2024;22:216\u201325.","journal-title":"J Natl Compr Canc Netw"},{"key":"7287_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ejrad.2017.10.019","volume":"97","author":"R Hartman","year":"2017","unstructured":"Hartman R, Kawashima A. Lower tract neoplasm: update of imaging evaluation. Eur J Radiol. 2017;97:119\u201330.","journal-title":"Eur J Radiol"},{"key":"7287_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.eururo.2006.05.021","volume":"51","author":"SF Shariat","year":"2007","unstructured":"Shariat SF, Palapattu GS, Karakiewicz PI, et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol. 2007;51:137\u201349. discussion 149\u2013151.","journal-title":"Eur Urol"},{"key":"7287_CR7","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/S0022-5347(05)67522-2","volume":"163","author":"ML Paik","year":"2000","unstructured":"Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol. 2000;163:1693\u20136.","journal-title":"J Urol"},{"key":"7287_CR8","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1148\/radiology.169.3.3186994","volume":"169","author":"JN Buy","year":"1988","unstructured":"Buy JN, Moss AA, Guinet C, et al. MR staging of bladder carcinoma: correlation with pathologic findings. Radiology. 1988;169:695\u2013700.","journal-title":"Radiology"},{"key":"7287_CR9","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1158\/0008-5472.CAN-14-3745","volume":"75","author":"YD Bhutia","year":"2015","unstructured":"Bhutia YD, Babu E, Ramachandran S, Ganapathy V. Amino acid transporters in Cancer and their relevance to glutamine addiction: novel targets for the design of a new class of anticancer drugs. Cancer Res. 2015;75:1782.","journal-title":"Cancer Res"},{"key":"7287_CR10","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.2967\/jnumed.115.170456","volume":"57","author":"GA Ulaner","year":"2016","unstructured":"Ulaner GA, Goldman DA, G\u00f6nen M, et al. Initial results of a prospective clinical trial of 18F-Fluciclovine PET\/CT in newly diagnosed invasive ductal and invasive lobular breast cancers. J Nucl Med. 2016;57:1350\u20136.","journal-title":"J Nucl Med"},{"key":"7287_CR11","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.2967\/jnumed.114.143628","volume":"55","author":"DM Schuster","year":"2014","unstructured":"Schuster DM, Nanni C, Fanti S, et al. Anti-1-Amino-3-(18)F-Fluorocyclobutane-1-Carboxylic acid: physiologic uptake patterns, incidental findings, and variants that May simulate disease. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2014;55:1986\u201392.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"key":"7287_CR12","doi-asserted-by":"crossref","unstructured":"Ng TS, Gao X, Salari K, Zlatev DV, Heidari P, Kamran SC. Incorporating PSMA-Targeting theranostics into personalized prostate Cancer treatment: a multidisciplinary perspective. Front Oncol 2021;11.","DOI":"10.3389\/fonc.2021.722277"},{"key":"7287_CR13","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1200\/JCO.2008.20.6722","volume":"27","author":"AS Kibel","year":"2009","unstructured":"Kibel AS, Dehdashti F, Katz MD, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography\/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol. 2009;27:4314\u201320.","journal-title":"J Clin Oncol"},{"key":"7287_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s10147-007-0720-8","volume":"13","author":"H Jadvar","year":"2008","unstructured":"Jadvar H, Quan V, Henderson RW, Conti PS. [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int J Clin Oncol. 2008;13:42\u20137.","journal-title":"Int J Clin Oncol"},{"key":"7287_CR15","first-page":"753","volume":"58","author":"A Civelek","year":"2017","unstructured":"Civelek A, Lin J, Agarwal P, Malayeri A, Apolo A. FDG PET-MRI in the management of patients with muscle invasive bladder cancer. J Nucl Med. 2017;58:753.","journal-title":"J Nucl Med"},{"key":"7287_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jphs.2022.10.002","volume":"150","author":"S Pae","year":"2022","unstructured":"Pae S, Sakamoto S, Zhao X, et al. Targeting L-type amino acid transporter 1 in urological malignancy: current status and future perspective. J Pharmacol Sci. 2022;150:251\u20138.","journal-title":"J Pharmacol Sci"},{"key":"7287_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","volume":"4","author":"MK Bakht","year":"2023","unstructured":"Bakht MK, Yamada Y, Ku S-Y, et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer. 2023;4:699\u2013715.","journal-title":"Nat Cancer"},{"key":"7287_CR18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1037\/0033-2909.88.2.322","volume":"88","author":"AJ Conger","year":"1980","unstructured":"Conger AJ. Integration and generalization of kappas for multiple raters. Psychol Bull. 1980;88:322.","journal-title":"Psychol Bull"},{"key":"7287_CR19","unstructured":"Gwet KL. Handbook of inter-rater reliability: the definitive guide to measuring the extent of agreement among raters. Fourth edition ed. Gaithersburg, MD: Advanced Analytics, LLC Gaithersburg, MD; 2014."},{"key":"7287_CR20","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2214\/AJR.19.21894","volume":"214","author":"MS Robertson","year":"2020","unstructured":"Robertson MS, Sakellis CG, Hyun H, Jacene HA. Extraprostatic uptake of 18F-fluciclovine: differentiation of nonprostatic neoplasms from metastatic prostate cancer. AJR Am J Roentgenol. 2020;214:641\u20138.","journal-title":"AJR Am J Roentgenol"},{"key":"7287_CR21","doi-asserted-by":"crossref","unstructured":"Zhao X, Sakamoto S, Maimaiti M, Anzai N, Ichikawa T. Contribution of LAT1-4F2hc in urological cancers via Toll-like receptor and other vital pathways. Cancers (Basel). 2022;14.","DOI":"10.3390\/cancers14010229"},{"key":"7287_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.euo.2022.04.008","volume":"5","author":"PJ Hensley","year":"2022","unstructured":"Hensley PJ, Panebianco V, Pietzak E, et al. Contemporary staging for muscle-invasive bladder cancer: accuracy and limitations. Eur Urol Oncol. 2022;5:403\u201311.","journal-title":"Eur Urol Oncol"},{"key":"7287_CR23","doi-asserted-by":"publisher","first-page":"912699","DOI":"10.3389\/fonc.2022.912699","volume":"12","author":"G Roviello","year":"2022","unstructured":"Roviello G, Catalano M, Santi R, et al. Neoadjuvant treatment in muscle-invasive bladder cancer: from the beginning to the latest developments. Front Oncol. 2022;12:912699.","journal-title":"Front Oncol"},{"key":"7287_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67\u201376.","journal-title":"Lancet"},{"key":"7287_CR25","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar AV, Castellano D, O\u2019Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483\u201392.","journal-title":"Lancet Oncol"},{"key":"7287_CR26","doi-asserted-by":"publisher","unstructured":"Geynisman DMAP, Ross EA et al. A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN). Journal of Clinical Oncology, Volume 41, Number 6_suppl https:\/\/doi.org\/10.1200\/JCO2.023416_suppl438","DOI":"10.1200\/JCO2.023416_suppl438"},{"key":"7287_CR27","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","volume":"29","author":"MD Galsky","year":"2023","unstructured":"Galsky MD, Daneshmand S, Izadmehr S, et al. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat Med. 2023;29:2825\u201334.","journal-title":"Nat Med"},{"key":"7287_CR28","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3390\/cancers15030566","volume":"15","author":"J Esteban-Villarrubia","year":"2023","unstructured":"Esteban-Villarrubia J, Torres-Jim\u00e9nez J, Bueno-Bravo C, Garc\u00eda-Mondaray R, Subiela JD, Gajate P. Current and future landscape of perioperative treatment for Muscle-Invasive bladder Cancer. Cancers (Basel). 2023;15:566.","journal-title":"Cancers (Basel)"},{"key":"7287_CR29","doi-asserted-by":"crossref","unstructured":"Lai AL, Mee LY. VI-RADS in bladder cancer: overview, pearls and pitfalls. Eur J Radiol 2023:110666.","DOI":"10.1016\/j.ejrad.2022.110666"},{"key":"7287_CR30","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2214\/AJR.16.17114","volume":"208","author":"CH Lee","year":"2017","unstructured":"Lee CH, Tan CH, Faria SC. Role of imaging in the local staging of urothelial carcinoma of the bladder. Am J Roentgenol. 2017;208:1193\u2013205.","journal-title":"Am J Roentgenol"},{"key":"7287_CR31","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1007\/s00259-005-1886-9","volume":"32","author":"O Drieskens","year":"2005","unstructured":"Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging. 2005;32:1412\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7287_CR32","doi-asserted-by":"publisher","first-page":"565086","DOI":"10.3389\/fonc.2020.565086","volume":"10","author":"A Girard","year":"2020","unstructured":"Girard A, Vila Reyes H, Shaish H, et al. The role of 18F-FDG PET\/CT in guiding precision medicine for invasive bladder carcinoma. Front Oncol. 2020;10:565086.","journal-title":"Front Oncol"},{"key":"7287_CR33","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1200\/JCO.2010.28.7052","volume":"28","author":"AB Apolo","year":"2010","unstructured":"Apolo AB, Riches J, Sch\u00f6der H, et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography in bladder cancer. J Clin Oncol. 2010;28:3973\u20138.","journal-title":"J Clin Oncol"},{"key":"7287_CR34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1053\/j.semnuclmed.2021.12.004","volume":"52","author":"K Bouchelouche","year":"2022","unstructured":"Bouchelouche K. PET\/CT in bladder cancer: an update. Semin Nucl Med. 2022;52:475\u201385.","journal-title":"Semin Nucl Med"},{"key":"7287_CR35","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1038\/s41598-020-58136-x","volume":"10","author":"M Maimaiti","year":"2020","unstructured":"Maimaiti M, Sakamoto S, Yamada Y, et al. Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma. Sci Rep. 2020;10:1292.","journal-title":"Sci Rep"},{"key":"7287_CR36","first-page":"603","volume":"13","author":"H Sawazaki","year":"2021","unstructured":"Sawazaki H, Arai Y, Ito Y, et al. Expression of L-Type amino acid transporter 1 is a predictive biomarker of intravesical recurrence in patients with Non-Muscle invasive bladder Cancer. Res Rep Urol. 2021;13:603\u201311.","journal-title":"Res Rep Urol"},{"key":"7287_CR37","doi-asserted-by":"publisher","first-page":"974338","DOI":"10.3389\/fcell.2022.974338","volume":"10","author":"R\u00c5 Jersin","year":"2022","unstructured":"Jersin R\u00c5, Jonassen LR, Dankel SN. The neutral amino acid transporter SLC7A10 in adipose tissue, obesity and insulin resistance. Front Cell Dev Biology. 2022;10:974338.","journal-title":"Front Cell Dev Biology"},{"key":"7287_CR38","doi-asserted-by":"publisher","first-page":"983023","DOI":"10.3389\/fonc.2023.983023","volume":"13","author":"S Jain","year":"2023","unstructured":"Jain S, Dhingra VK. An overview of radiolabeled amino acid tracers in oncologic imaging. Front Oncol. 2023;13:983023.","journal-title":"Front Oncol"},{"key":"7287_CR39","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s11255-017-1637-4","volume":"49","author":"EEF van de Putte","year":"2017","unstructured":"van de Putte EEF, Vegt E, Mertens LS, et al. FDG-PET\/CT for response evaluation of invasive bladder cancer following neoadjuvant chemotherapy. Int Urol Nephrol. 2017;49:1585\u201391.","journal-title":"Int Urol Nephrol"},{"key":"7287_CR40","doi-asserted-by":"crossref","unstructured":"Marandino L, Capozza A, Bandini M et al. [18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. Urol Oncol. 2021;39:235.e215-235.e221.","DOI":"10.1016\/j.urolonc.2020.09.035"},{"key":"7287_CR41","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/bju.16363","volume":"134","author":"M Longoni","year":"2024","unstructured":"Longoni M, Scilipoti P, Re C, et al. Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET\/CT for lymph node assessment before radical cystectomy in bladder cancer patients. BJU Int. 2024;134:636\u201343.","journal-title":"BJU Int"},{"key":"7287_CR42","first-page":"250","volume":"11","author":"AJ Tulipan","year":"2021","unstructured":"Tulipan AJ, Salberg UB, Hole KH, et al. Amino acid transporter expression and 18F-FACBC uptake at PET in primary prostate cancer. Am J Nucl Med Mol Imaging. 2021;11:250\u20139.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"7287_CR43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13550-019-0518-5","volume":"9","author":"I Saarinen","year":"2019","unstructured":"Saarinen I, Jambor I, Kim M, et al. Correlation between (18)F-1-amino-3-fluorocyclobutane-1-carboxylic acid ((18)F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer. EJNMMI Res. 2019;9:50.","journal-title":"EJNMMI Res"},{"key":"7287_CR44","doi-asserted-by":"crossref","unstructured":"Katal S, Eibschutz LS, Saboury B, Gholamrezanezhad A, Alavi A. Advantages and applications of Total-Body PET scanning. Diagnostics (Basel). 2022;12.","DOI":"10.3390\/diagnostics12020426"},{"key":"7287_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00259-020-04843-6","volume":"48","author":"A Dimitrakopoulou-Strauss","year":"2021","unstructured":"Dimitrakopoulou-Strauss A, Pan L, Sachpekidis C. Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives. Eur J Nucl Med Mol Imaging. 2021;48:21\u201339.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7287_CR46","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder Cancer. N Engl J Med. 2003;349:859\u201366.","journal-title":"N Engl J Med"},{"key":"7287_CR47","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1158\/1078-0432.CCR-22-1973","volume":"29","author":"S Chopra","year":"2023","unstructured":"Chopra S, Trepka K, Sakhamuri S, et al. Theranostic targeting of CUB Domain-Containing protein 1 (CDCP1) in multiple subtypes of bladder Cancer. Clin Cancer Res. 2023;29:1232\u201342.","journal-title":"Clin Cancer Res"},{"key":"7287_CR48","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.2967\/jnumed.124.267474","volume":"65","author":"A Piccardo","year":"2024","unstructured":"Piccardo A, Bottoni G, Puppo C, et al. Role of (64)CuCl(2) PET\/CT in detecting and staging Muscle-Invasive bladder cancer: comparison with Contrast-Enhanced CT and (18)F-FDG PET\/CT. J Nucl Med. 2024;65:1357\u201363.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07287-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07287-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07287-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T11:46:19Z","timestamp":1757159179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07287-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["7287"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07287-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"8 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Dana-Farber\/Harvard Cancer Center Institutional Review Committee (IRB, DF19-208). It is registered on clinicaltrials.gov (\n                      \n                        NCT04018053 Registered 2\/26\/2020\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"HJ is on the SNMMI Board of Directors and is a consultant for Blue Earth Diagnostics. HB has received funding from Blue Earth Diagnostics for unrelated projects. TN has received support from Bayer and Lantheus for unrelated projects.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}